Showing results (81-90 of 152) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|April 1, 2011
Boceprevir for previously treated chronic HCV genotype 1 infectionBruce R Bacon, Stuart C Gordon, Eric Lawitz, et al.Gastroenterology|March 16, 2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePaul J Pockros, K Rajender Reddy, Parvez S Mantry, et al.Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.Alimentary Pharmacology & Therapeutics|March 2, 2022
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairmentMark Sulkowski, Laura E Telep, Massimo Colombo, et al.Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.Hepatology (Baltimore, Md.)|August 13, 2011
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Richard E Nettles, Min Gao, Marc Bifano, et al.Medicine|July 3, 2019
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillanceNicole Loo, Bryan Hanysak, Jena Mann, et al.Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.Hepatology (Baltimore, Md.)|October 23, 2016
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.Kidney International Reports|February 19, 2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseEric Lawitz, Edward Gane, Eric Cohen, et al.Pageof 16